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Botulinum toxin (BT-A) is a neurotoxin which is produced by the Gram-positive anaerobic bacterium Clostridium botulinum. The
eﬃcacy of Botulinum toxin in treating hyperhidrosis and the glabellar lines is well known and FDA approved.
Because BT-A inhibits the release of acetylcholine and many other neurotransmitters such as norepinephrine and substance P at the
level of nerve ending, this toxin has been used to treat a lot of dermatological disorders which are thought to be triggered by these
neurotransmitters.
In this article we are discussing the medical oﬀ-label uses of BT-A in dermatology.
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Botulinum toxin (BT-A) is a neurotoxin which is pro-
duced by the Gram-positive anaerobic bacteria Clostridium
botulinum. C. botulinum bacteria produce neurotoxins
which cause Botulism; a disease that is characterized by
potentially life-threatening neuroparalysis.
There are seven distinct serotypes of Botulinum toxin :
A, B, C1, D, E, F, and G. Human botulism is caused
mainly by types A, B, E, and (rarely) F Aoki, 2001.
C. botulinum bacterium was ﬁrst identiﬁed in 1895 and
was isolated in the 1920s. In 1989 Food and Drug
Administration (FDA) approved the use of Botulinum
toxin (BOTOX) for treatment of strabismus and
blepharospasm.
In 2002 was the ﬁrst dermatological and Cosmetic FDA
approval of Botulinum toxin (BOTOX) for moderate to
severe glabellar lines. And in 2004 it was approved for
axillary hyperhidrosis.
2. Types of Botulinum toxin
As we said , there are 7 serotypes of Botulinum toxin A,
B, C1, D, E, F, and G , but the commercially available
Botulinum toxins are only from type A – mainly – and
type B.
The most widely used Botulinum toxins commercially
are:
1. Onabotulinumtoxin A (Botox)
2. Abobotulinumtoxin A (Dysport)
3. Incobotulinumtoxin A (Xeomin)
4. Rimabotulinumtoxin B (Myobloc)
3. Mechanism of action of Botulinum toxin
Botulinum toxin is a single-chain protein that is inactive
until cleaved by its own proteases into one heavy and one
light chain. Once the toxin enters the nerves by binding to
surface protein receptors or endocytosis into internalized
vesicles (Eric, 2006).
The light chain is released into the nerve cytosol, and the
SNARE (soluble N-ethylmaleimide-sensitive factor
attachment protein receptor) protein complex is cleavedto inhibit exocytosis of the neurotransmitters such as
acetylcholine.
Type A toxin cleaves SNAP-25 (synaptosome-associated
protein of 25 KDa), whereas type B cleaves VAMP (ves-
icle-associated membrane protein).
These proteins are necessary for the release of acetylcho-
line from vesicles within the cytoplasm of the motor
nerve endings Fig. 1.
The end results are chemoprevention of cholinergic neu-
rons which lead to temporary paralysis of the targeted
skeletal muscles, decreased sweating or decrease in the
pain at the site of injection.
3.1. Non dermatological uses
The ﬁrst FDA approval of Botulinum toxin was in 1989
for strabismus and blepharospasm which are non-dermato-
logic conditions, since that time many medical and surgical
specialties have tried Botulinum toxin in a lot of speciﬁc
conditions in their ﬁelds, the non dermatological indica-
tions of BT-A are listed in Table 1.
3.2. Dermatological uses
The ﬁrst FDA approval for Botulinum toxin in
dermatology and dermatological surgery was in 2002
for Cosmetic treatment of moderate to severe glabellar
lines, and in 2004 it was approved to treat severe
primary axillary hyperhidrosis (Teo et al., 2012; Ney
et al., 2007).
Based on the mechanism of action that has been dis-
cussed above, Botulinum toxin has been tested in many
skin conditions in a lot of case reports and case series ,
but the use of Botulinum toxin in all of these disorders is
still oﬀ-label.
We can divide the skin diseases in which Botulinum
toxin was tested as one of the treatment options into two
groups (Table 2).
1. Sweating related disorders.
2. Pain and itchiness related disorders.
These oﬀ-label disorders will be discussed in this article,
but the discussion of the cosmetic and FDA approved con-
ditions is beyond the scope of this article.
Figure 1. Mechanism of action of Botulinum toxin. The light chain of (BT- A) cleaves SNAP-25 and consequently prevents the release of ACh into the
neuromuscular junction.
Table 1
Non dermatological uses of Botulinum toxin.
Ophthalmology Neurology Urology and Gynaecology Gastrointestinal
 Blepharospasm
 Reduce lid retraction
 Apraxia of lid opening
 Exposure keratopathy
 Lower lid spastic entropion
 Infantile esotropia
 Intermittent exotropia
 Nerve palsies
 Congenital nystagmus
 Lacrimal hypersecretion
 Pain relief in acute angle closure glaucoma
 Hemifacial spasm
 Facial asymmetry
 Oromandibular dystonia
 Cervical dystonia
 Spasmodic torticollis
 Achalasia
 Gustatory sweating
 Synkinesia
 Headache
 Detrusor overactivity
 Detrusor sphincter dyssenergia
 Bladder overactivity
 Painful bladder syndrome
 Pelvic pain
 Outﬂow obstruction symptoms
 Urinary retention
 Achalasia
 Anal ﬁssure
 Biliary dyskinesia
Table 2
Dermatological uses.
FDA approved use of Botulinum toxin
 Axillary hyperhydrosis
 Glabellar lines
Dermatological uses
Oﬀ-label uses
Sweating related disorders Pain and itchiness related disorders
1. Hailey-Hailey
2. Dyshidrotic hand eczema (pompholyx)
3. Granulosis rubra nasi
4. Pitted keratolysis
5. Chromhidrosis
6. Inverse Psoriasis
7. Eccrine hydrocystomas
8. Eccrine Angiomatous Hamartoma
9. Aquagenic syringeal acrokeratoderma
 Post-herpetic Neuralgia
 Leiomyoma-related pain
 Lichen simplex chronicus
 Raynaud Syndrome
 Notalgia Paresthetica
 Thelalgia
 Brachioradial pruritus
 Vulvodynia
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3.3.1. Hailey-Hailey disease
Hailey-Hailey disease or familial benign pemphigus is a
chronic autosomal dominant disorder in which there is
loss-of-function and mutations in the ATP2C1 gene. The
skin lesions in this chronic disorder are frequently induced
or exacerbated by UV exposure, sweating, friction, and
skin infection.
Many topical and systemic therapies have been pro-
posed with limited success.
Because Hailey-Hailey disease is induced by excess
sweating Botulinum toxin type A has been evaluated to
treat Hailey-Hailey disease in many case reports, In 6
patients with extensive Hailey-Hailey disease resistant to
multiple therapeutic regimens; Abobotulinumtoxin A was
started in all six cases as adjuvant treatment and there
was a marked improvement achieved of the lesions with
few side eﬀects in all patients (Smith et al., 2004).
In another study 3 patients with axillary and/or inguinal
benign familial pemphigus responded favorably to treat-
ment with subcutaneous botulinum toxin type A (Onabo-
tulinumtoxin A) (Qureshi, 2002) Fig. 2.
Many additional case reports showed the same beneﬁ-
cial eﬀect of Botulinum toxin as one of the treatment
options for Hailey-Hailey disease (Grunfeld, 2009; Doft,
2012; Koeyers et al., 2008; Lo´pez-Ferrer, 2012).
3.3.2. Multiple eccrine hidrocystomas
Eccrine hidrocystoma is a benign cystic lesion which can
be either solitary (Smith type) or multiple (Robinson type).
Multiple eccrine hidrocystomas are characterized by
chronic course and seasonal variability in which it is asso-
ciated with warm climates and hyperhidrosis. It occurs
mainly in middle-aged women in the centrofacial area.
The eﬃcacy of Botulinum toxin type A was evaluated in
many reports of multiple facial hidrocystomas with excel-
lent outcome (Bessa et al., 2010; Pe´rez-Robayna, 2010;
Lapiere et al., 2000; Konrad et al., 2001).Figure 2. Erythematous–violaceous plaques and erosions in the axilla in a
patient with Hailey-Hailey disease before treatment and clinical resolution
of the erosions after injection of Botulinum toxin. Photograph courtesy of
Dr. A. Lo´pez-Ferrer Servicio de Dermatologı´a, Hospital de la Santa Creu
i Sant Pau, Barcelona, Spain.In one study on 22 patients (16 F and 6 M) with eccrine
hydrocystoma documented pathologically and the patients
were divided into two groups, with 12 pts in the and 10 pts
in the 2nd group. BT-A (Abobotulinumtoxin A) was
injected perilesionally and intradermally at a concentration
of 5 and 10 units in 0.01 ml respectively.
There was excellent response at ﬁrst session in around
80% of both groups with mean duration of 7 months of
the drug eﬃcacy (Correia et al., 2009).
In another case report of two female patients with multi-
ple facial eccrine hidrocystomas, both of them were
injected with BTX-A (Onabotulinumtoxin A) with excel-
lent results within one week of injection and the eﬃcacy
duration was 6 months in both patients (Blugerman,
2003) Fig. 3.
3.3.3. Dyshidrotic eczema (Pompholyx)
Pompholyx or Dyshidrotic Eczema (DE) is a relapsing
vesicular eruption on the hands or feet, most often without
erythema. The acrosyringium is not involved in the patho-
genesis of pompholyx, but hyperhidrosis is an aggravating
factor in nearly 40% of these cases.
Botulinum toxin had been used for the treatment of
pompholyx in many studies, ten patients with pompholyx
were treated on one hand with intradermal BT-A (mean,
162 U Onabotulinumtoxin) with the untreated hand as a
control. At follow-up 5 to 6 weeks after injection showed
that 7 of 10 patients experienced good or very good eﬀect
(Ebrahimi, 2010).
It was shown that BT-A was eﬀective as an adjuvant
treatment not as single agent; 8 patients were treated with
topical steroids in both hands and BT-A injection in the
more aﬀected hand.
The mean DASI score (Dyshidrotic Eczema Area and
Severity Index) changed from 28 to 17 with topical therapy
alone and from 36 to 3 with adjuvant BT-A. Also itching
and vesiculation were inhibited and relapses have not been
seen in the BT-A group (Woolery-Lloyd, 2009).Figure 3. (A and B) Multiple, dome-shaped, bluish to skin-colored
papules, over the periorbital areas and bilateral cheeks. (C) Signiﬁcant
lesional fading was achieved 7 days after injection. (Photograph courtesy
of Dr. Ta-Ju LiuChang Gung University, College of Medicine,
Kaohsiung, Taiwan with permission).
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Chromhidrosis is a rare disorder characterized by the
excretion of pigmented sweat. It is frequently conﬁned to
the face or axillae. The colored sweat may be yellow, blue,
green, or black. There is a debate wither the origin of the
sweating in chromhidrosis is eccrine or apocrine, but most
likely it originates from the apocrine gland due to the pres-
ence of lipofuscin granules which are responsible for the
pigmented sweat (Kavoussi, 2013).
The mechanism of action of BT-A in chromhidrosis is
by inhibiting the expression of adrenergic receptors and
blocking the release of norepinephrine and substance P
because the apocrine glands are unresponsive to cholinergic
stimulation (Liu, 2009).
Many case reports showed the eﬀectiveness of BT-A in
treating chromhidrosis, the eﬀect of BT-A in all reports
was noted within 7 days and the eﬀect was maintained
for up to 4 months (Swartling et al., 2002; Wollina, 2002;
Pe´rez-Tato, 2012).
3.3.5. Inverse psoriasis
Inverse psoriasis or ﬂexural psoriasis is a form of psori-
asis that involves the skin folds and ﬂexor surfaces such as
the axillae and groins.
Because this variant of psoriasis is exacerbated by
humidity and sweating BT-A has been tried to treat this
type of Psoriasis.
BT-A in Inverse psoriasis may act at the neuroglandular
junction level to reduce local sweating with its consequent
skin maceration and secondary infection and at the extra-
junction level to inhibit the liberation of neuropeptides
and other pro-algogenic substances responsible for inﬂam-
mation and hyperkeratosis.
Fifteen patients with a conﬁrmed diagnosis of inverse
psoriasis were enrolled into one study. The psoriasis was
located in several areas , a total dosage of BT-A between
50 and 100 U per patient depending on the extent and
severity of the psoriasis was injected, Subjective symptom-
atology improved in all patients and erythema extension,
intensity and inﬁltration improved in 13 of 15 patients
(87%). Treatment was well tolerated with no reported
adverse events (Aoki, 1962).
The same result was seen in one patient treated with BT-
A for inverse psoriasis in his axillae which was completely
cleared within 4 weeks (Pe´rez-Tato, 2012).
Few additional skin conditions such as Granulosis rubra
nasi (Matarasso, 2005), pitted keratolysis (Wu et al., 2005),
and Eccrine Angiomatous Hamartoma (Zanchi et al.,
2008), have been mentioned to show a favorable response
to BT-A injection, but because the eﬃcacy of BT-A was
evaluated in only a single case report for each condition,
we will not discuss the details of these diseases.
3.3.6. Bromhidrosis
Axillary bromhidrosis means the oﬀensive odor that
arises from apocrine glands, it is a common problem
that causes a serious personal and social handicap. Themechanism of action in this condition is the same with
chromhidrosis since in both conditions the origin of sweat-
ing is the apocrine glands.
Sixty-seven patients with axillary bromhidrosis were
injected intracutaneously with 50 U of BTX-A into each
axilla. After BT-A injection, the malodor was eliminated
in 73% of patients (Saber, 2011).
In a randomized double-blinded study 16 healthy volun-
teers were injected with Botulinum toxin A (Abobotuli-
numtoxin A) in one axilla and 0.9% sodium chloride
solution in the other axilla in, after 7 days a signiﬁcant
reduction of odor intensity was observed for the Botulinum
toxin A-treated side (Grazziotin, 2009).
In a diﬀerent case report there was an improvement of
localized foul odor in the genital hair bearing area in one
patient who was treated with Botulinum toxin A
(Tamura, 2004). Although the oﬀensive odor in the
genital area is multifactorial in which hyperhidrosis and
bromhidrosis cause part of the problem personal hygiene
and bacterial over activity play an important role in this
condition.
3.4. Pain and Itchiness related disorders
3.4.1. Post-herpetic Neuralgia
Post-herpetic Neuralgia (PHN) is the most common
neurologic complication of Herpes Zoster which is deﬁned
as pain persisting beyond 4 weeks, occurred in 16% of
patients younger than 60 years but in 47% of those older
than 60 years (Barco, 2009).
BT-A has been widely used in many clinical neuropathic
disorders including migraine, trigeminal neuralgia, etc.
based on these studies BT-A use in neuropathic pain was
reported in many randomized, double-blind, placebo-con-
trolled trials and case reports.
30 adults with PHN were randomized either to BT-A or
placebo. Severity of pain was evaluated by patients using a
visual analogue scale (VAS) and quality of sleep was
assessed using a 5-item questionnaire. Thirteen patients
from the experimental arm achieved an at least 50% reduc-
tion in VAS score, compared with none of the placebo
patients. BTX-A patients showed a signiﬁcant reduction
in sleep scores between baseline and week 2, which
remained unchanged until 16th week (He et al., 2012).
The therapeutic beneﬁts of BT-A were investigated in
subjects with PHN in another randomized, double-blind,
placebo-controlled study. Sixty subjects with PHN were
randomly and evenly distributed into BTX-A, lidocaine,
and placebo groups.
After randomization, one of the following solutions was
injecting subcutaneously in the aﬀected dermatome: 5 u/
mL BTX-A, 0.5% lidocaine, or 0.9% saline (placebo).
Visual analog scale (VAS) pain and sleeping time (hours)
were evaluated at the time of pretreatment, day 1, day 7,
and 3 months post treatment.
There was a signiﬁcant reduction in the pain and sleep
time in the BT-A treated group in comparison to the
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same results were seen in many case reports (Lee, 2004;
Watson and Evans, 1986).
3.4.2. Lichen simplex chronicus (LSC)
LSC is an eczematous dermatosis characterized by
intense localized pruritus. The sensation of pruritus in
LSC has been shown recently to be related to acetylcholine
sensitive C-ﬁbers.
Only single study was published regarding the use of
BT-A for LSC, in this study Botulinum toxin type A
(Abobotulinumtoxin A) was injected intradermally into 5
lesions in 3 patients, no corticosteroids or any other speciﬁc
topical therapy was administered, Pruritus subsided within
3 to 7 days in all 3 patients, Within 2 to 4 weeks all lesions
cleared completely and no recurrences were noted over a 4-
month follow-up (Apalla et al., 2013). Therapeutic eﬃcacy
of BT-A as an antipruritic agent in LSC needs larger place-
bocontrolled randomized trials.
3.4.3. Raynaud Syndrome
Raynaud Syndrome is a vasospastic disorder of the ﬁn-
gers, toes, and other body sites often associated with expo-
sure to cold temperatures or emotional stress, leading to
persistent pain and ulceration.
Raynaud’s phenomenon usually presented clinically as a
digital pain which is associated with sequential pallor, cya-
nosis, and erythema, and less commonly, acral ulceration.
Following a precipitating vasoconstricting stimulus,
small-caliber digital arteries undergo an exaggerated
response of vasospasm. This decreases blood ﬂow and the
digits appear ischemic or white. As the trapped blood
becomes increasingly deoxygenated, the digits will then
turn cyanotic or blue, and ﬁnally red following reperfusion
hyperemia.Table 3
Summary of the studies that were made to evaluate the eﬀect of BT-A in case
Study No. of patients
Serri et al. (2013) 18 pts with systemic sclerosis
Neumeister (2010) A total of 33 pts (14 men and 19 women)
Neumeister et al. (2009) 19 pts
Fregene et al. (2009) 26 pts
Van Beek et al. (2007) 11 patients
Kossintseva (2008) One patient
Jenkins (2013) 10 pts randomized controlled study
Smith (2012) Single female ptCutaneous vasoconstriction and vasodilation are regu-
lated by modulation of sympathetic and parasympathetic
neuronal inputs and the complex actions of released acetyl-
choline (Ach), noradrenaline (NE), peptides, and small
molecules such as nitric oxide on vascular smooth muscle.
The mechanism of action of BT-A in Raynaud’s
phenomenon
Local BT-A injection consistently shows an ability to
improve perfusion of the injected tissue by both substantial
opening of the vascular bed by inhibiting expression of
adrenergic receptors in the vessel wall and blocking the
release of norepinephrine and substance P, glutamate,
and calcitonin gene-releasing peptide (Xiao et al., 2010).
Since 2004, there have been a lot of studies that have
evaluated the use of Botulinum toxin A for the treatment
of Raynaud’s. All showed overall improvement in patient
pain as well as a reduction in soft tissue ulceration
(Sotiriou, 2009).
Most of these studies are case series (Liu, 2006;
Heckmann et al., 2002; Kossintseva et al., 2011; Iorio
et al., 2012; Serri et al., 2013) , one is randomized controlled
trial (Neumeister, 2010) and two case reports (Neumeister
et al., 2009; Fregene et al., 2009) (Table 3). In all of these
studies the patients were presented with chronic ischemic
hand pain, ulceration and loss of function.
The eﬃcacy of BT-A in treating these patients was by
measuring the level of pain, cutaneous temperatures, color,
and ulcerations before and after the injection. The range of
the dose was 50–100 u per each hand injected in most of
these studies following the distribution of the superﬁcial
palmar arch (Fig. 4).
Most of the patients in all of these studies experienced
improved vascularity (tissue perfusion), relief of pain and
ulcerations, most of the patients remained pain-free for
many months.s of Raynaud’s phenomenon.
Results
Thirty days after injection, complete healing of ulcers occurred and the
symptomatology signiﬁcantly improved
All but 5 patients experienced improved vascularity and relief of pain
84% reported pain reduction at rest and improvement of the perfusion
and ulcerations
Statistically signiﬁcant improvements were noted for pain score and
digit transcutaneous oxygen saturation
All patients reported highly signiﬁcant pain reduction and 9 pts with
ulcers spontaneously healed
The BT-A treated hand had reduced swelling, color change, and pain,
whereas the untreated control hand remained aﬀected
There was a signiﬁcant increase in digital pulp temperatures of the
hands treated with and there was no statistically signiﬁcant diﬀerence in
cold recovery times between the digits of treatment and control hands
There was an immediate decrease in pain after administration of BT-A
along with a rapid and prolonged increase in tissue perfusion lasting
months to years
Figure 4. Injection of Botulinum toxin-A in Raynaud Syndrome into the web spaces (red dots) and around neurovascular bundles (blue dots).
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BT-A was found to be a safe and eﬀective therapy with-
out signiﬁcant local or systemic side eﬀects. Although it is
FDA approved in certain conditions, it is had been used
as an oﬀ-label modality of treatment in many skin diseases;
most of these conditions are either exacerbated by excess
sweating or they are pain related disorders andmost of these
disorders are resistant to many diﬀerent treatment ways.
Based on this we advice not to use BT-A routinely in the
conditions that were discussed earlier in this article, since
the use of BT-A in these oﬀ-label conditions needs larger
and randomized controlled trials, but keep this modality
of treatment as the last option when the regular modalities
of treatment fail or there is a clear contraindication to
use.
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